Transcriptomic analysis uncovers dysregulated glycosylation pathways in clear cell renal cell carcinoma
Journal of Biological Chemistry · 2026-11 · 302 (11) · 113620
DOI: 10.1016/j.jbc.2026.113620 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2026-11. Verfasst von Ru M Wen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Stanford University School of Medicine, Stanford, California, USA; Department of Biomedical Data Science, Stanford University …. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Peter Michael Foundation, Hearst Foundations, National Library of Medicine.
Abstract (Originalsprache)
Clear cell renal cell carcinoma (ccRCC) is the most common subtype of kidney cancer and is characterized by altered metabolism, immune remodeling, and aberrant glycosylation. Although glycosylation regulates tumor-cell signaling, adhesion, angiogenesis, and immune recognition, its relationship with the ccRCC immune microenvironment remains incompletely defined. Here, we analyzed RNA-sequencing profiles from ccRCC tumors and adjacent normal kidney tissues. Glycan-related genes and glycogenes involved in glycan biosynthesis distinguished ccRCC tumors from normal tissues and revealed altered sulfatase, nucleotide sugar, glycosyltransferase, glycosaminoglycan pathways. CIBERSORTx analysis showed distinct immune cell distributions in tumors, and Spearman correlation analysis linked glycosylation pathway activity with immune cell abundance. Glycogene expression further classified ccRCC tumors into two subtypes with different immune signatures, Siglec expression patterns, and overall survival. The transcriptional differences between normal and tumor tissues are dominated by immune/inflammatory activation and ion/membrane transport regulation. Our results underscore the importance of targeting cancer-associated changes in glycosylation machinery using novel strategies to improve the specificity and efficacy of cancer therapeutics in ccRCC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, Stanford University School of Medicine, Stanford, California, USA; Department of Biomedical Data Science, Stanford University School of Medicine, Stanford, California, USA. Electronic address: r.w…
- Department of Molecular and Cellular Physiology, Stanford University, Stanford, California, USA; Department of Cell Biology and Physiology, Washington University School of Medicine, St Louis, Missouri, USA.
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California, USA.
- Department of Urology, Stanford University School of Medicine, Stanford, California, USA.
- Department of Urology, Stanford University School of Medicine, Stanford, California, USA; Canary Center at Stanford for Cancer Early Detection, Stanford University School of Medicine, Stanford, California, USA. Electron…
Förderung
- The Peter Michael Foundation
- Hearst Foundations
- National Library of Medicine
Zitieren
APA
Wen, R. M., Marti, G. E. W., Nolley, R., Lam, N., Zhao, H., Peehl, D. M., & Brooks, J. D. (2026). Transcriptomic analysis uncovers dysregulated glycosylation pathways in clear cell renal cell carcinoma. Journal of Biological Chemistry, 302(11), 113620. https://doi.org/10.1016/j.jbc.2026.113620
Vancouver
Wen RM, Marti GEW, Nolley R, Lam N, Zhao H, Peehl DM, et al. Transcriptomic analysis uncovers dysregulated glycosylation pathways in clear cell renal cell carcinoma. Journal of Biological Chemistry. 2026;302(11):113620. doi:10.1016/j.jbc.2026.113620
BibTeX
@article{Wen2026,
author = {Wen, Ru M and Marti, G Edward W and Nolley, Rosalie and Lam, Nathan and Zhao, Hongjuan and Peehl, Donna M and Brooks, James D},
title = {Transcriptomic analysis uncovers dysregulated glycosylation pathways in clear cell renal cell carcinoma},
journal = {Journal of Biological Chemistry},
year = {2026},
volume = {302},
number = {11},
pages = {113620},
doi = {10.1016/j.jbc.2026.113620}
}
EUVIMED